BenevolentAI Ltd (BenevolentAI) is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s drug programs include BEN2293 (atopic dermatitis), BEN8744 (ulcerative colitis), BEN9160 (amyotrophic lateral sclerosis), glioblastoma multiforme, inflammatory bowel disease, CNS diseases, antiviral, nonalcoholic steatohepatitis (NASH), oncology, Parkinson’s disease, chronic kidney disease, idiopathic pulmonary fibrosis, and others. BenevolentAI’s platform enables scientists to design and develop new treatments for patients, using a large amount of extracted and deduced biomedical information. The company operates in the UK and the US. BenevolentAI is headquartered in London, England, the UK.

Headquarters United Kingdom

Address 4-8 Maple Street, London, W1T5HD


Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange BAI (AMS)

Net Income (2020) XXX

Market Cap* $582.0M

   

   

* As of and is in US$

Access premium data and analytics for BenevolentAI Ltd

20+

Pipeline Drugs

Identify which of BenevolentAI Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

5

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for BenevolentAI Ltd’s relevant decision makers and contact details.

5

Clinical Trials

Determine BenevolentAI Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

90+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on BenevolentAI Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services
BEN2293 (Atopic Dermatitis) Research
BEN8744 (Ulcerative Colitis)
BEN9160 (Amyotrophic Lateral Sclerosis)
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Acquisitions/Mergers/Takeovers In April, the company merged with Odyssey Acquisition SA.
2022 Acquisitions/Mergers/Takeovers In April, the company merged with BenevolentAI Ltd.
2022 Contracts/Agreements In January, the company and AstraZeneca announced the expansion of their artificial intelligence-powered drug discovery partnership.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters BenevolentAI Ltd Acacia Pharma Group PLC 4D Pharma Plc Aria Pharmaceuticals Inc Cresset BioMolecular Discovery Ltd
Headquarters United Kingdom United Kingdom United Kingdom United States of America United Kingdom
City London Cambridge Leeds Palo Alto Litlington
State/Province - - - California Cambridgeshire
No. of Employees - - 95 - 31
Entity Type Public Private Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
François Nader Chairman Executive Board - -
Joanna Shields Director; Chief Executive Officer Executive Board 2018 60
Nick Keher Chief Financial Officer Senior Management 2022 -
Ivan Griffin Chief Operating Officer Senior Management - -
Daniel Neil Chief Technology Officer Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer